Agios Pharmaceuticals, Inc. is a biopharmaceutical company that pioneers therapies targeting cellular metabolism to treat rare genetic diseases, with a primary focus on classical hematology. The company's business model centers on the discovery, development, and commercialization of small-molecule medicines. Its flagship commercial product is mitapivat, an activator of wild-type and mutant pyruvate kinase (PK) enzymes. Mitapivat is marketed as PYRUKYND for the treatment of hemolytic anemia in adults with PK deficiency, and as AQVESME for adults with thalassemia. Agios generates 100% of its product revenue from sales of mitapivat, primarily in the United States with select international sales. The company previously maintained an oncology portfolio, which it divested to Servier Pharmaceuticals in 2021 to concentrate exclusively on rare genetic diseases. Agios is actively advancing its clinical pipeline, which includes tebapivat (a next-generation PK activator) and other candidates targeting sickle cell disease and pediatric PK deficiency. Geographically, the company is headquartered in Cambridge, Massachusetts, and markets its therapies directly in the U.S. while partnering for commercialization in other regions. Its competitive position relies on its proprietary PK activator platform and a strong balance sheet funded by the strategic sale of its oncology business and royalty rights.
